sis; however, there were no examples of enamides derived
from enones.5
recently reported an important subclass of the phenolic
tetrahydrofluorenones in which an alkyl bridge connects C9a
and C2 5.9,10 In the course of our efforts to make bridged
analogues in the fused-pyrazolo-class 8, we encountered
difficulties that forced us to improve their synthesis. Initially,
we had successfully prepared compounds represented by 8
from a C9a-alkoxy intermediate 6 which often required
protection as an acetate or benzyl ether. To undergo an
intramolecular alkylation reaction the C9a-alkoxy substituent
was converted to a mesylate or a triflate to obtain the desired
bridged compound. In some cases, this route was complicated
by the formation of a cyclic ether 7 by intramolecular
Michael reaction of carbinol 6.11 Often, but not always, the
resulting ether could be opened and thus remain synthetically
useful. However, this undesired reaction prompted us to
explore a route to 8 that would feature the use of a
tetrahydrofluorenone intermediate 9 substituted with a C9a-
alkyl fluoride, which would serve as the latent bridging ring.
We demonstrated the effectiveness of this strategy by the
synthesis of 13, an important intermediate in the preparation
of C9a-C2 ethyl-bridged pyrazolotetrahydrofluorenones
(Scheme 2).
Halogen exchange of alkyl fluorides is also known.6 Boron
trihalides are particularly effective for this reaction, owing
in part to the strength of the resulting boron-fluoride bond.6c
However, this reaction has seen limited use in synthesis.7
One potential novel application of this reaction would be to
use an alkyl fluoride appended to a synthetic intermediate
so that it can be later activated for intramolecular alkylation.
In this way the fluoride would represent a valuable alternative
to a protected alkoxide with several important advantages:
alkyl fluorides are relatively stable to a variety of conditions,
they are often more easily introduced than their alkoxy
counterparts, and they can be directly activated to a better
leaving group without the need for a deprotection step.
Furthermore this tactic would be particularly useful in cases
where a free hydroxyl group would not be tolerated, e.g.,
due to incompatible functionality.
Scheme 1
Scheme 2
Phenolic tetrahydrofluorenones 3 and fused pyrazolotet-
rahydrofluorenones 4 are potent selective classes of ligands
for the estrogen receptor ꢀ (ERꢀ) (Scheme 1.8 We have
Pyrazoloindanone 10,12 was alkylated with fluoroethyl
bromide to give 11, which was converted to the tetrahydrof-
(4) (a) Terao, J.; Watabe, H.; Kambe, N. J. Am. Chem. Soc. 2005, 127,
3656–3657. (b) Terao, J.; Kambe, N. Bull. Chem. Soc. 2006, 79, 663–672.
(5) Hatakeyama, T.; Ito, S.; Yamane, H.; Nakamura, M.; Nakamura, E.
Tetrahedron. 2007, 63, 8440–8448.
(6) (a) Olah, G. A.; Narang, S. C.; Field, L. D. J. Org. Chem. 1981, 46,
3727–3728. (b) Rozov, L. A.; Lessor, R. A.; Kudzma, L. V.; Ramig, K. J.
Fluorine Chem. 1998, 88, 51–54. (c) Namavari, M.; Satyamurthy, N.; Barrio,
J. R. J. Fluorine Chem. 1995, 72 (1), 89–93.
(9) Wildonger, K. J.; Ratcliffe, R. W.; Mosley, R. T.; Hammond, M. L.;
Birzin, E. T.; Rohrer, S. P. Bioorg. Med. Chem. Lett. 2006, 16, 4462–
4466
.
(10) We have referred to compounds in this paper as substituted
derivatives of 1,2,9,9a-tetrahydro-3H-fluoren-3-ones. The IUPAC name for
the ring system represented by 9 is 8,9,9a,10-tetrahydroindeno[2,1-e]indazol-
7(3H)-one; the ring system of 13 is 3,9,10,11-tetrahydro-8,10a-methanoa-
zuleno[2,1-e]indazol-7(8H)-one; 15 is a 2,8,9,10,11,12-hexahydro-7H-8,11a-
methanocycloocta[3,4]cyclopenta[1,2-e]indazol-7-one; 18a is a gibba-
1,3,4a(10a),4b-tetraen-6-one-methane (1:2); 18c is a 7,8,9,10-tetrahydro-
7,10a-methanocycloocta[a]inden-6(11H)-one.
(7) Theodoridis, G. Tetrahedron Lett. 1998, 39, 9365–9368.
(8) (a) Wilkening, R. R.; Ratcliffe, R. W.; Tynebor, E. C.; Wildonger,
K. J.; Fried, A. K.; Hammond, M. L.; Mosley, R. T.; Fitzgerald, P. M. D.;
Sharma, N.; McKeever; Nilsson, S.; Carlquist, M.; Thorsell, A.; Locco, L.;
Katz, R.; Frisch, K.; Birzin, E. T.; Wilkinson, H. A.; Mitra, S.; Cai, S.;
Hayes, E. C.; Schaeffer, J. M.; Rohrer, S. P Bioorg. Med. Chem. Lett. 2006,
16, 3489–3494. (b) Wilkening, R. R.; Ratcliffe, R. W.; Fried, A. K.; Meng,
D.; Sun, W.; Colwell, L.; Lambert, S.; Greenlee, M.; Nilsson, S.; Thorsell,
A.; Mojena, M.; Tudela, C.; Frisch, K.; Chan, W.; Birzin, E. T.; Rohrer,
S.; Hammond, M. L Bioorg. Med. Chem. Lett. 2006, 16, 3896–3901.
(11) Mori et al. observed a similar result. See ref 2.
(12) Experimental details for the preparation of 10 are included in the
Supporting Information.
2984
Org. Lett., Vol. 10, No. 14, 2008